Forest COPD Combo Hits Roadblock En Route To NDA Filing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Forest is delaying submission of an NDA for aclidinium/formoterol to resolve FDA concerns about the formulation’s chemistry, manufacturing and control specifications.